Eribulin mesylate in patients with refractory cancers: a Phase I study

por Mukohara, Toru, Nagai, Shunji, Mukai, Hirofumi, Namiki, Masayuki, Minami, Hironobu
Publicado 2011

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

por Matsubara, Nobuaki, Mukai, Hirofumi, Naito, Yoichi, Nezu, Masahiko, Itoh, Kuniaki
Publicado 2013

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC...

por Narui, Kazutaka, Ishikawa, Takashi, Taira, Naruto, Uemura, Yukari, Mukai, Hirofumi
Publicado 2022

A deep learning-based automated diagnostic system for classifying mammographic lesions

por Yamaguchi, Takeshi, Inoue, Kenichi, Tsunoda, Hiroko, Uematsu, Takayoshi, Shinohara, Norimitsu, Mukai, Hirofumi
Publicado 2020

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation

por Fujii, Satoshi, Yamashita, Satoshi, Yamaguchi, Takeshi, Takahashi, Masato, Hozumi, Yasuo, Ushijima, Toshikazu, Mukai, Hirofumi
Publicado 2017

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

por Saeki, Toshiaki, Araki, Kazuhiro, Shimada, Ken, Shigekawa, Takashi, Nakayama, Hirofumi, Segawa, Yoshihiko, Mukai, Hirofumi
Publicado 2016

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial

por Kawahara, Takuya, Taira, Naruto, Shiroiwa, Takeru, Hagiwara, Yasuhiro, Fukuda, Takashi, Uemura, Yukari, Mukai, Hirofumi
Publicado 2022

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open‐label phase 2 trial

por Tamura, Kenji, Hasegawa, Kosei, Katsumata, Noriyuki, Matsumoto, Koji, Mukai, Hirofumi, Takahashi, Shunji, Nomura, Hiroyuki, Minami, Hironobu
Publicado 2019

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer

por Mukai, Hirofumi, Saeki, Toshiaki, Shimada, Ken, Naito, Yoichi, Matsubara, Nobuaki, Nakanishi, Tadashi, Obaishi, Hiroshi, Namiki, Masayuki, Sasaki, Yasutsuna
Publicado 2014

Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan

por Mizota, Yuri, Ohashi, Yasuo, Iwase, Takuji, Iwata, Hiroji, Sawaki, Masataka, Kinoshita, Takayuki, Taira, Naruto, Mukai, Hirofumi, Yamamoto, Seiichiro
Publicado 2017

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer

por Sasaki, Akinori, Harano, Kenichi, Kogawa, Takahiro, Matsubara, Nobuaki, Naito, Yoichi, Hosono, Ako, Mukai, Hirofumi, Yoshino, Takayuki, Mukohara, Toru
Publicado 2020

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

por Inoue, Kenichi, Takahashi, Masato, Mukai, Hirofumi, Yamanaka, Takashi, Egawa, Chiyomi, Sakata, Yukinori, Ikezawa, Hiroki, Matsuoka, Toshiyuki, Tsurutani, Junji
Publicado 2020

Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trial...

por Kawahara, Takuya, Iwamoto, Takayuki, Takashima, Ikumi, Hanazawa, Ryoichi, Uemura, Kohei, Uemura, Yukari, Mukai, Hirofumi, Kikawa, Yuichiro, Taira, Naruto
Publicado 2022

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabin...

por Iwata, Hiroji, Fujii, Hirofumi, Masuda, Norikazu, Mukai, Hirofumi, Nishimura, Yuichiro, Katsura, Koichi, Ellis, Catherine E., Gagnon, Robert C., Nakamura, Seigo
Publicado 2013

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

por Matsubara, Nobuaki, Mukai, Hirofumi, Hosono, Ako, Onomura, Mai, Sasaki, Masaoki, Yajima, Yoko, Hashizume, Kensei, Yasuda, Masanobu, Uemura, Miho, Zurth, Christian
Publicado 2017

Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC...

por Hagiwara, Yasuhiro, Shiroiwa, Takeru, Shimozuma, Kojiro, Kawahara, Takuya, Uemura, Yukari, Watanabe, Takanori, Taira, Naruto, Fukuda, Takashi, Ohashi, Yasuo, Mukai, Hirofumi
Publicado 2017

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvan...

por Watanabe, Toru, Kuranami, Masaru, Inoue, Kenichi, Masuda, Norikazu, Aogi, Kenjiro, Ohno, Shinji, Iwata, Hiroji, Mukai, Hirofumi, Uemura, Yukari, Ohashi, Yasuo
Publicado 2017

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry

por Ohsumi, Shozo, Watanabe, Kenichi, Kondo, Naoto, Kosaka, Yoshimasa, Ishikawa, Takashi, Kitahara, Miyuki, Kubo, Shinichiro, Oba, Mari S., Kimura, Tetsuya, Takita, Atsushi, Mukai, Hirofumi
Publicado 2023

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors

por Yoshino, Takayuki, Kojima, Takashi, Bando, Hideaki, Yamazaki, Tomoko, Naito, Yoichi, Mukai, Hirofumi, Fuse, Nozomu, Goto, Koichi, Ito, Yuko, Doi, Toshihiko, Ohtsu, Atsushi
Publicado 2016

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors

por Mukai, Hirofumi, Kato, Ken, Esaki, Taito, Ohsumi, Shouzou, Hozomi, Yasuo, Matsubara, Nobuaki, Hamaguchi, Tetsuya, Matsumura, Yasuhiro, Goda, Rika, Hirai, Takayuki, Nambu, Yoshihiro
Publicado 2016